Can a higher dose of xolair beat food allergies?

NCT ID NCT06943534

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if higher doses of omalizumab (Xolair) can help people with food allergies tolerate more of their trigger foods. Thirty participants with allergies to peanut, cashew, walnut, egg, or milk will receive either 5 mg/kg or 15 mg/kg of omalizumab for 16 weeks. The goal is to see if they can then eat at least 600 mg of the allergen without a reaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omalizumab (Xolair)
What this could lead to: If successful, this could lead to a more effective dosing strategy for omalizumab, helping people with food allergies tolerate larger amounts of trigger foods without severe reactions.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Higher doses may also increase side effects or fail to improve tolerance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease food allergy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIES FOOD ALLERGY

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27599, United States
University of Texas Southwestern
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.